- 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
- 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
* Health Benefits of Quitting Quitting brings immediate health benefits at any age. [Schroeder 483A] 1 year after cessation, coronary disease risk drops to ? of smokers All-cause death rate declines within first 2 years Stroke risk declines at a comparable rate In addition to extra years of life, quality of life is another benefit After 15 years of abstinence, the coronary disease risk falls to the rate of people who never smoked. [Schroeder 483B] Smokers who quit at age 65 can anticipate 4 years more life than those who continue to smoke. [Schroeder 483E] The rate of cancers falls by 50% after a decade of abstinence. [Schroeder 483E] Schroeder SA. What to do with a patient who smokes. JAMA. 2005;294(4):482-487. Schroeder 483A Schroeder 483B Schroeder 483C Schroeder 483D Schroeder 483C Slide 64 from SMOKING_CESSATION_09[1].26.05_Final * * Key Point Smoking cessation can lead to a reduction in mortality in people with mild-to-moderate airway obstruction. The Lung Health Study (LHS) was a randomized, multicenter clinical trial designed to determine whether a smoking cessation intervention program with or without the regular use of a bronchodilator can slow the rate of FEV1 decline over 5 years in smokers in the early stages of COPD. The authors also assessed the long-term effect of this smoking cessation program on mortality 14.5 years after initial evaluation. Smokers (N=5887) aged 35 to 60 years with airway obstruction defined as FEV1 of 55% to 90% of predicted and FEV1/FVC 0.70 were randomly assigned to 1 of 3 groups: usual care, smoking intervention and the inhaled bronchodilator ipratropium bromide, smoking intervention and an inhaled placebo. Participants were classified as sustained quitters if they were not smoking at all annual visits and continuous smokers if they were still smoking at all annual visits. Intermittent quitters reported smoking at some but not all of their follow-up visits or during the time between visits. Mortality was 6.04 per 1000 perso
文档评论(0)